Candriam S.C.A. Raises Stock Holdings in Immunome, Inc. $IMNM

by · The Cerbat Gem

Candriam S.C.A. increased its stake in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 170.2% during the 3rd quarter, Holdings Channel reports. The firm owned 859,527 shares of the company’s stock after purchasing an additional 541,441 shares during the quarter. Candriam S.C.A.’s holdings in Immunome were worth $10,065,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the last quarter. Brighton Jones LLC purchased a new position in Immunome in the second quarter worth $98,000. SG Americas Securities LLC bought a new position in Immunome in the third quarter valued at $103,000. Finally, Whalen Wealth Management Inc. purchased a new stake in Immunome during the second quarter valued at about $128,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Price Performance

IMNM opened at $24.93 on Wednesday. The stock’s 50 day simple moving average is $22.30 and its 200 day simple moving average is $16.29. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -8.45 and a beta of 2.32. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $27.65.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Leerink Partners set a $40.00 price objective on Immunome in a report on Monday, December 15th. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Immunome in a research note on Thursday, January 15th. Truist Financial began coverage on shares of Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 price target on the stock. Guggenheim boosted their price objective on shares of Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Stephens increased their target price on shares of Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a report on Monday, November 17th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Check Out Our Latest Report on Immunome

Insider Activity

In other news, CEO Clay B. Siegall bought 4,729 shares of the business’s stock in a transaction dated Tuesday, December 30th. The shares were purchased at an average price of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the acquisition, the chief executive officer owned 665,254 shares of the company’s stock, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the transaction, the director directly owned 2,031,181 shares in the company, valued at approximately $44,157,874.94. The trade was a 15.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders purchased 68,518 shares of company stock valued at $1,453,958. 7.69% of the stock is currently owned by company insiders.

Immunome Company Profile

(Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

See Also

Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM – Free Report).